Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:147
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 28 条
[1]   AZATHIOPRINE IN THE TREATMENT OF PEMPHIGUS VULGARIS - A LONG-TERM FOLLOW-UP [J].
ABERER, W ;
WOLFFSCHREINER, EC ;
STINGL, G ;
WOLFF, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1987, 16 (03) :527-533
[2]   Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus [J].
Arin, MJ ;
Engert, A ;
Krieg, T ;
Hunzelmann, N .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) :620-625
[3]   The role of IVIg treatment in severe pemphigus vulgaris [J].
Baum, S ;
Scope, A ;
Barzilai, A ;
Azizi, E ;
Trau, H .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (05) :548-552
[4]   A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus [J].
Beissert, Stefan ;
Werfel, Thomas ;
Frieling, Uta ;
Boehm, Markus ;
Sticherling, Michael ;
Stadler, Rudolf ;
Zillikens, Detlev ;
Rzany, Berthold ;
Hunzelmann, Nicolas ;
Meurer, Michael ;
Gollnick, Harald ;
Ruzicka, Thomas ;
Pillekamp, Hans ;
Junghans, Volker ;
Luger, Thomas A. .
ARCHIVES OF DERMATOLOGY, 2006, 142 (11) :1447-1454
[5]   IVIg treatment of pemphigus: How it works & how to use it [J].
Bystryn, JC ;
Rudolph, JL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) :1093-1098
[6]   Treatment of pemphigus with intravenous immunoglobulin [J].
Bystryn, JC ;
Jiao, D ;
Natow, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) :358-363
[7]   The adjuvant therapy of pemphigus - An update [J].
Bystryn, JC ;
Steinman, NM .
ARCHIVES OF DERMATOLOGY, 1996, 132 (02) :203-212
[8]   Influence of treatment on the clinical course of pemphigus vulgaris [J].
Carson, PJ ;
Hameed, A ;
Ahmed, AR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (04) :645-652
[9]  
Chams-Davatchi C, 2002, ANN DERMATOL VENER, V129, P23
[10]  
Chrysomallis Fotis, 1994, International Journal of Dermatology, V33, P803, DOI 10.1111/j.1365-4362.1994.tb01003.x